BB Biotech AG

BB Biotech AG is a Swiss-based investment company that specializes in the biotechnology sector. With a history dating back to 1993, it stands among the largest and most established investors focused exclusively on biotech worldwide. The company primarily targets listed biotechnology firms that are actively developing and commercializing innovative drugs, with an emphasis on addressing significant medical needs in areas such as oncology, neurological and metabolic disorders, cardiovascular and infectious diseases, and autoimmune conditions. BB Biotech AG pursues a long-only, long-term investment strategy, with a portfolio often consisting of around 20 to 35 companies, and a substantial share allocated to core holdings in North American and Western European markets. Investment decisions are made by Bellevue Asset Management, guided by experienced directors and a dedicated research team. By concentrating on rapidly growing biotech enterprises and breakthrough therapeutic approaches like RNA, gene, and cell-based technologies, BB Biotech AG plays a critical role in providing capital to advance medical innovation across the global healthcare landscape.